BL22

WikiDoc Resources for BL22
Articles
Most recent articles on BL22 Most cited articles on BL22 Review articles on BL22 Articles on BL22 in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on BL22 Images of BL22 Photos of BL22 Podcasts & MP3s on BL22 Videos on BL22
Evidence Based Medicine
Cochrane Collaboration on BL22 Bandolier on BL22 TRIP on BL22
Clinical Trials
Ongoing Trials on BL22 at Clinical Trials.gov Trial results on BL22 Clinical Trials on BL22 at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on BL22 NICE Guidance on BL22 NHS PRODIGY Guidance FDA on BL22 CDC on BL22
Books
Books on BL22
News
BL22 in the news Be alerted to news on BL22 News trends on BL22
Commentary
Blogs on BL22
Definitions
Definitions of BL22
Patient Resources / Community
Patient resources on BL22 Discussion groups on BL22 Patient Handouts on BL22 Directions to Hospitals Treating BL22 Risk calculators and risk factors for BL22
Healthcare Provider Resources
Symptoms of BL22 Causes & Risk Factors for BL22 Diagnostic studies for BL22 Treatment of BL22
Continuing Medical Education (CME)
CME Programs on BL22
International
BL22 en Espanol BL22 en Francais
Business
BL22 in the Marketplace Patents on BL22
Experimental / Informatics
List of terms related to BL22

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

BL22, also called CAT-3888 or GCR-3888, is an immunotoxin which attaches to and, upon internalization, kills B cells. It has completed a Phase I clinical (human) trial and is currently in a Phase II clinical trial for the treatment of hairy cell leukemia at a Phase I clinical trial for pediatric acute lymphoblastic leukemia and non-Hodgkin's lymphoma[3] at the NIH in the U.S. It may be useful against any B cell leukemia or lymphoma.

Technically, BL22 is an anti-CD22 immunotoxin fusion protein between a murine anti-CD22 disulphide-linked Fv (dsFv) antibody fragment and an edited copy of bacterial Pseudomonas exotoxin PE38. The toxin is activated intracellularly, by the low pH of the lysosome into which the entire protein was internalized via the CD22 receptor. The toxin kills the targeted cell through ribosome inactivation.[4]

BL22 is very similar to the newer HA22, which changes one amino acid in the antibody fragment to increase the binding affinity for the target molecule. Both of these proteins are designed to bind to the CD22 receptor on the surface of B cells.

Business History

BL22 was initially designed and produced at the U.S. National Cancer Institute, one of the agencies which make up the NIH. Early development of BL22 was funded by California biotech Genencor.[5] The future drug was acquired by Cambridge Antibody Technology at the end of 2005; less than a year later, CAT was purchased by British pharmaceutical company AstraZeneca.[6]

Template:WikiDoc Sources